- Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
- Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
- Turnstone Biologics Appoints William Waddill to its Board of Directors
- Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
- Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.
- Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference
- Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
- Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber
- Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
More ▼
Key statistics
On Wednesday, Turnstone Biologics Corp (TSBX:NMQ) closed at 2.25, 38.46% above the 52 week low of 1.63 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.40 |
---|---|
High | 2.41 |
Low | 2.25 |
Bid | 2.30 |
Offer | 2.78 |
Previous close | 2.25 |
Average volume | 271.25k |
---|---|
Shares outstanding | 23.13m |
Free float | 22.24m |
P/E (TTM) | -- |
Market cap | 52.04m USD |
EPS (TTM) | -3.53 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼